Jupiter Neurosciences (JUNS) Cash from Operations (2023 - 2025)
Jupiter Neurosciences (JUNS) posted quarterly Cash from Operations of 2368023.0 for Q4 2025, up 35.93% year-over-year from 1742137.69 in Q4 2024, and down 105.12% quarter-over-quarter from 1154450.0 in Q3 2025.
Jupiter Neurosciences (JUNS) Cash from Operations (2023 - 2025) Analysis & Trends
Jupiter Neurosciences (JUNS) has reported Cash from Operations for 3 consecutive years, with 2368023.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 35.93% year-over-year to 2368023.0; the TTM figure through Dec 2025 stood at 5413736.0 (down 38.42% YoY), while the FY2025 annual figure was 5413736.0, down 38.42% from the prior year.
- Cash from Operations eased to 2368023.0 in Q4 2025 per JUNS's latest filing, from 1154450.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 42598.0 in Q3 2024 and bottomed at 3695779.0 in Q4 2024.
- Historically, Cash from Operations has averaged 1053986.33 across 3 years, with a median of 828222.0 in 2025.
- On a YoY basis, Cash from Operations climbed as much as 35.93% in 2025 and fell as far as 2610.1% in 2025.
- Jupiter Neurosciences' Cash from Operations stood at 161137.0 in 2023, then plunged by 2193.56% to 3695779.0 in 2024, then surged by 35.93% to 2368023.0 in 2025.
- Business Quant data shows JUNS's Cash from Operations at 2368023.0 in Q4 2025, 1154450.0 in Q3 2025, and 828222.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Jupiter Neurosciences | 3.37 Mn | 1.85 Mn | 21,064.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -2.37 Mn |
| Dec 31, 2025 | -2.37 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -828,222.00 |
| Jun 30, 2025 | -828,222.00 |
| Mar 31, 2025 | -1.06 Mn |
| Mar 31, 2025 | -1.06 Mn |
| Dec 31, 2024 | -3.70 Mn |
| Dec 31, 2024 | -3.70 Mn |
| Sep 30, 2024 | -42,598.00 |
| Sep 30, 2024 | -42,598.00 |
| Jun 30, 2024 | -107,462.00 |
| Jun 30, 2024 | -107,462.00 |
| Mar 31, 2024 | -65,165.00 |
| Mar 31, 2024 | -65,165.00 |
| Dec 31, 2023 | -161,137.00 |
| Dec 31, 2023 | -161,137.00 |